All In Biotech

Drug Trial Radar · NCT04221919

Different β -Blockers in STEMI and Primary PCI

Different β -Blockers in Patients With ST-segment Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Last checked: Nov 19, 2026Latest source record: Jan 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,200

Planned (sponsor's estimate)

Start

Jan 2020

Primary completion

Jan 2021

Study completion Jan 2025

Sponsor

Lead sponsor
Qilu Hospital of Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily

Conditions

  • Primary PCI

Interventions

  • β -BlockersDrug

    Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in LVEDV from baselineTime frame: 1 to 5 years
  2. Major adverse cardiovascular events (MACE)Time frame: 1 to 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.